---
title: 'Software Daily Summary: What Happened on October 30, 2026'
headline: Brox.AI builds a physician panel for digital-clone research
description: A biopharma essay argues AI could add drug candidates faster than the
  industry can improve R&D productivity.
url: https://thebench.bio/news/software/2026-10-30
topic: software
date: '2026-10-30'
covers:
- '2026-10-30'
date_published: '2026-10-30T12:04:13Z'
date_modified: '2026-10-30T12:04:13Z'
tags:
- Software
- Industry
sources: 3
publisher: TheBench.Bio
---

# Software Daily Summary: What Happened on October 30, 2026

**Brox.AI builds a physician panel for digital-clone research**

A biopharma essay argues AI could add drug candidates faster than the industry can improve R&D productivity.

## Today in brief

Brox.AI says it has recruited 80 US physicians who prescribe a specialized pancreatic cancer therapy for a digital-clone research panel. [1] [2] A LifeSciVC essay predicts AI will weaken industry-wide R&D productivity over the next three to five years, before improving it over the longer term. [3]

## Also worth knowing

- CEO Hamish Brocklebank said physicians can query their clones through Brox.AI’s Melivora and request removal of their data. He said building a high-quality clone takes four to five hours, and Brox.AI can pay physicians $2,000 or more per hour, compared with about $500 at a typical research firm. [1] [2]
- The essay’s author argues AI may intensify competition around established drug targets. Better medicines and any gains in development productivity could take years to assess. [3]

## The day in numbers

- **80 of about 1,000**: Physicians recruited for Brox.AI’s specialized pancreatic cancer prescriber panel, according to Brocklebank. [1] [2]
- **3–5 years**: Period in which the LifeSciVC essay’s author expects AI to weaken overall biopharma R&D productivity. [3]

## Sources

1. [Three Levels of Digital Clone Use Cases: Q&A with Hamish Brocklebank](<https://www.pharmexec.com/view/three-levels-digital-clone-use-cases-hamish-brocklebank>), Pharmaceutical Executive, 2026-10-30
2. [How Digital Twins Impact Recruiting During Research](<https://www.pharmexec.com/view/digital-twins-impact-recruiting-during-research>), Pharmaceutical Executive, 2026-10-29
3. [The Fruits of AI Drug Abundance: Indigestion In The Near Term](<https://lifescivc.com/2026/10/the-fruits-of-ai-drug-abundance-indigestion-in-the-near-term/?utm_source=rss&utm_medium=rss&utm_campaign=the-fruits-of-ai-drug-abundance-indigestion-in-the-near-term>), LifeSciVC, 2026-10-30

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmexec.com/view/three-levels-digital-clone-use-cases-hamish-brocklebank>
[2]: <https://www.pharmexec.com/view/digital-twins-impact-recruiting-during-research>
[3]: <https://lifescivc.com/2026/10/the-fruits-of-ai-drug-abundance-indigestion-in-the-near-term/?utm_source=rss&utm_medium=rss&utm_campaign=the-fruits-of-ai-drug-abundance-indigestion-in-the-near-term>